Private company

Orgenesis Inc.

Orgenesis Inc. is an American pharmaceutical preparations company based in Germantown.2

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersCarson City, United States2
  • Incorporated inNV3
  • Business address20271 Goldenrod Lane, Germantown, Md 208763
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300DCE2FRWERKD7842
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Business Filings Incorporated, 89701 Carson City, United States2
  • Registered withBusiness Center (Secretary of State), E0375472008-92

See how the biggest companies compare on our leaderboards

Islets: The FDA-cleared Koligo platform, with over 80 patients treated at hospitals across the US.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-86.3%Gross margin5
-3842.3%Operating margin5
-4653.6%Net margin5
95.3%Revenue growth, 20245
-$17.3MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue7¢$1.9M
  • Research and development36¢$9.6M
  • Selling, general and admin56¢$14.8M
  • Income tax0¢$97.0K

Out of $1.0M in revenue.5 The company lost money this year.

Financial statements

Revenue6789105$1.0M in 2024−94% since 2018
0$10.0M$20.0M$30.0M$40.0M2018: $18.7M$18.7M20182019: $2.6M$2.6M2019−86%2020: $6.2M$6.2M2020+135%2021: $31.6M$31.6M2021+412%2022: $36.0M$36.0M2022+14%2023: $530.0K$530.0K2023−99%2024: $1.0M$1.0M2024+95%
Gross profit11105-$893.0K in 2024
-$10.0M0$10.0M$20.0M$30.0M$40.0M2018: $7.8M$7.8M20182022: $30.9M$30.9M2022+294%2023: -$5.7M-$5.7M20232024: -$893.0K-$893.0K2024−84%
Operating income6789105-$39.8M in 2024+186% since 2018
-$100.0M-$50.0M0$50.0M2018: -$13.9M-$13.9M20182019: $22.0M$22.0M20192020: -$95.8M-$95.8M20202021: -$16.8M-$16.8M2021−82%2022: -$10.1M-$10.1M2022−40%2023: -$53.6M-$53.6M2023+431%2024: -$39.8M-$39.8M2024−26%
Net income6789105-$48.2M in 2024+163% since 2018
-$60.0M-$40.0M-$20.0M0$20.0M$40.0M2018: -$18.3M-$18.3M20182019: $24.1M$24.1M20192020: $1.1M$1.1M2020−95%2021: -$18.1M-$18.1M20212022: -$14.9M-$14.9M2022−18%2023: -$55.4M-$55.4M2023+272%2024: -$48.2M-$48.2M2024−13%
Fiscal year2018201920202021202220232024
Revenue$18.7M6$2.6M7$6.2M8$31.6M9$36.0M10$530.0K5$1.0M5
Cost of revenue$10.8M6$18.2M6$36.6M9$5.1M10$6.3M5$1.9M5
Gross profit$7.8M11$30.9M10-$5.7M5-$893.0K5
Research and development$6.5M6$14.0M7$84.0M8$36.6M8$21.9M10$10.6M5$9.6M5
Selling, general and admin$11.5M7$19.0M8$14.7M9$15.6M10$35.1M5$14.8M5
Operating income-$13.9M6$22.0M7-$95.8M8-$16.8M9-$10.1M10-$53.6M5-$39.8M5
Income before tax-$18.0M9-$12.0M10-$64.4M5-$48.9M5
Income tax$1.3M6$229.0K7-$1.6M8$108.0K9$209.0K10$473.0K5$97.0K5
Net income-$18.3M6$24.1M7$1.1M8-$18.1M9-$14.9M10-$55.4M5-$48.2M5
Earnings per share-$1.436$1.777-$0.298$0.749$0.5910$19.085$11.445
Earnings per share (diluted)-$1.436-$1.776$0.5910$19.085$11.445
Shares (weighted, basic)24.3M shares925.1M shares102.9M shares54.2M shares5
Shares (weighted, diluted)25.1M shares102.9M shares54.2M shares5

Compare Orgenesis Inc. with another company

Corporate structure

Orgenesis Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Orgenesis Inc.

  • Neurocords LLC Filed SCHEDULE 13G on Orgenesis Inc., latest Mar 14, 2025
  • JSAF Holdings, LLC Filed SC 13G/A on Orgenesis Inc., latest Dec 4, 2024
  • Jacob Safier Filed SC 13G/A on Orgenesis Inc., latest Dec 4, 2024 (2 filings since Feb 14, 2024)
  • Dimensions Trading New Filed SC 13G/A on Orgenesis Inc., latest Sep 7, 2023 (2 filings since Nov 21, 2022)
  • NewTech Investment Holdings, LLC Filed SC 13G on Orgenesis Inc., latest Jan 19, 2023
  • Bergen Asset Management, LLC Filed SC 13G/A on Orgenesis Inc., latest Feb 14, 2022
  • Orgenesis Inc. Carson City, Nevada, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Orgenesis Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$13.2M5 Dec 31, 2024$2.0M5 Dec 31, 2023+542.1%
Accumulated depreciation$12.6M5 Dec 31, 2024$575.0K5 Dec 31, 2023+2088.9%
Property and equipment, net$578.0K5 Dec 31, 2024$1.5M5 Dec 31, 2023−60.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$78.0K5 Dec 31, 2024$837.0K5 Dec 31, 2023−90.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$11.1M5 Dec 31, 2024$9.3M5 Dec 31, 2023+18.5%
Accumulated amortization$11.1M5 Dec 31, 2024$2.0M5 Dec 31, 2023+463.3%

Properties, in its own words

We do not own any real property. A description of the leased premises we utilize in several of our facilities is as follows:

Entity · Property Description

The rest of Item 2

Orgenesis Inc. · ● · Our principal office is located at 20271 Goldenrod Lane, Germantown, MD 20876.

Orgenesis Maryland LLC · ● · FastForward laboratory and office located at 1812 Ashland Ave, Baltimore, Maryland 21205.

● · Natick, Massachusetts

Mida Biotech BV · Laboratories and offices located in Leiden, The Netherlands

We believe that our facilities are generally in good condition and suitable to carry on our business. We also believe that, if required, suitable alternative or additional space will be available to us on commercially reasonable terms.

Item 2 of the 10-K filed Mar 26, 2026.4

Leadership

Who has led Orgenesis Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jacob Benairie2012–2013
  2. Sav Dipasquale2013
  3. Vered Caplan2017–2024

Chair

  1. Vered Caplan2018–2024

President

  1. Gilbert Adrias Cuison2011
  2. Jacob Benairie2012–2013
  3. Sav Dipasquale2013

Chief financial officer

  1. Dov Weinberg2013
  2. Joseph Tenne2014
  3. Neil Reithinger2019–2022
  4. Elliot Maltz2023
  5. Victor Miller2024
201520202025
Board members and other officers (19)

Former names

  • Business Outsourcing Service, Inc.Apr 2, 2009 to Aug 19, 20113

Timeline

  1. Jun 2, 20268-K Bylaws or fiscal year changed; Shareholder vote42
  2. Mar 13, 20268-K Executive or director change43
  3. Jan 26, 20268-K Entered a material agreement; Unregistered sale of shares44
  4. Sep 16, 20258-K Entered a material agreement; New debt or obligation45
  5. Aug 25, 20258-K Executive or director change46
  6. Aug 19, 20258-K Executive or director change47
  7. Aug 1, 20258-K Other events48
  8. Jun 6, 20258-K Listing notice or transfer49
  9. Apr 22, 20258-K Other events50
  10. Mar 6, 20258-K Entered a material agreement; Completed an acquisition or sale51
  11. Jan 28, 20258-K Entered a material agreement52
  12. Dec 27, 20248-K Executive or director change53
  13. Jun 12, 2017New chief executive Vered Caplan becomes CEO15
  14. Jan 3, 2013New chief executive Sav Dipasquale becomes CEO16
  15. Mar 28, 2012New chief executive Jacob Benairie becomes CEO17

Calendar

When it reported results

  1. Mar 30, 2022Reported quarterly or annual results54

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

177 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 67 major events, 46 insider forms, 8 large holders, 3 private raises, 36 other. The latest 20:

  1. Jun 2, 20268-K EDGAR
  2. May 20, 2026DEFR14A EDGAR
  3. May 5, 2026DEF 14A EDGAR
  4. Apr 16, 2026PRE 14A EDGAR
  5. Mar 26, 202610-K EDGAR
  6. Mar 13, 20268-K EDGAR
  7. Jan 26, 20268-K EDGAR
  8. Sep 16, 20258-K EDGAR
  9. Aug 25, 20258-K EDGAR
  10. Aug 19, 20258-K EDGAR
  11. Aug 1, 20258-K EDGAR
  12. Jun 6, 20258-K EDGAR
  13. May 16, 2025NT 10-Q EDGAR
  14. Apr 22, 20258-K EDGAR
  15. Apr 1, 2025NT 10-K EDGAR
  16. Mar 18, 20253 EDGAR
  17. Mar 14, 2025SCHEDULE 13G EDGAR
  18. Mar 6, 20258-K EDGAR
  19. Jan 28, 20258-K EDGAR
  20. Dec 27, 20248-K EDGAR

The 177 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

36 open-market trades by officers, directors and large owners since October 2021: 33 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 24, 2024Safier Jacob10% ownerBuy10,000$0.58$5.8KForm 4
Jun 24, 2024Safier Jacob10% ownerSale10,000$0.58$5.8KForm 4
Apr 16, 2024Safier Jacob10% ownerBuy10,000$0.51$5.1KForm 4
Apr 16, 2024Safier Jacob10% ownerSale10,000$0.50$5.0KForm 4
Apr 10, 2024Safier Jacob10% ownerBuy10,000$0.59$5.9KForm 4
Apr 10, 2024Safier Jacob10% ownerSale10,000$0.54$5.4KForm 4
Feb 1, 2024Safier Jacob10% ownerBuy10,100$0.33$3.3KForm 4
Jan 31, 2024Safier Jacob10% ownerBuy5,000$0.35$1.8KForm 4
Jan 30, 2024Safier Jacob10% ownerBuy25,000$0.33$8.2KForm 4
Jan 26, 2024Safier Jacob10% ownerBuy25,000$0.32$8.0KForm 4
Jan 25, 2024Safier Jacob10% ownerBuy25,000$0.32$8.0KForm 4
Jan 22, 2024Safier Jacob10% ownerBuy10,000$0.29$2.9KForm 4
Jan 18, 2024Safier Jacob10% ownerBuy10,000$0.33$3.3KForm 4
Jan 11, 2024Safier Jacob10% ownerBuy2,000$0.33$660Form 4
Jan 10, 2024Safier Jacob10% ownerBuy10,000$0.37$3.7KForm 4
Dec 21, 2023Safier Jacob10% ownerBuy10,000$0.45$4.5KForm 4
Dec 12, 2023Safier Jacob10% ownerBuy3,000$0.54$1.6KForm 4
Dec 11, 2023Safier Jacob10% ownerBuy2,000$0.53$1.1KForm 4
Dec 1, 2023Safier Jacob10% ownerBuy1,016$0.46$467Form 4
Nov 24, 2023Safier Jacob10% ownerBuy5,000$0.54$2.7KForm 4

All 36 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 3, 2024Raised $2.3 million in a private offering of equity Form D: 46 investors so far Form D
  2. Aug 31, 2023Raised $1 million in a private offering of equity Form D: 1 investor so far Form D
  3. Mar 30, 2022Raised $14.8 million in a private offering of equity Form D: 2 investors so far Form D

SEC filer profile

How Orgenesis Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROrgenesis Inc.1
  • CIK0001460602
  • Employer ID (EIN)98-05831664
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inNevada4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address20271 Goldenrod Lane, Germantown, MD 208761
  • Phone(480) 659-64041
  • Shares outstanding9,799,538 shares as of Mar 26, 20264
  • Public float$7.6M as of Jun 30, 20244
  • AuditorKesselman & Kesselman, Haifa, Israel PCAOB ID 1309; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceApr 2, 20091
  • Filings531 in all: 8-K (176), 4 (70), 10-Q (46), 3 (33), SC 13D (17), 10-K (16), UPLOAD (16), CORRESP (15)1
    All 42 form types

    EFFECT (11), DEF 14A (10), NT 10-Q (10), 10-Q/A (9), DEFA14A (9), 424B3 (8), D (8), S-3 (7), SC 13G/A (7), 5 (6), SC 13G (6), PRE 14A (5), 4/A (4), 424B5 (4), NT 10-K (4), S-1/A (4), SC 13D/A (4), 8-K/A (3), 3/A (2), ARS (2), POS AM (2), PRER14A (2), S-1 (2), S-3/A (2), S-8 (2), 10-K/A (1), 25-NSE (1), 424B2 (1), 8-A12B (1), 8-A12G (1), CERT (1), DEFR14A (1), NT 10-Q/A (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2026
    Quarterly report (10-Q) Nov 13, 2024
    Proxy statement (DEF 14A) May 5, 2026
    Latest 8-K (8-K) Jun 2, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareORGS

From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Orgenesis Inc. names in Item 1A of its 10-K filed Mar 26, 2026: 48 risks under these headings, as written.4

  • Risks Related to Our Company and POCare Business
  • We do not currently have sufficient funds to service our operations and our expenses and other liquidity needs and require additional capital immediately. Our management, as of December 31, 2024, and our independent registered public accounting firm, in its report on our financial statements as of and for the fiscal year ended December 31, 2024, have concluded that there is substantial doubt as to our ability to continue as a going concern.
  • Our POCare business has a limited operating history and an unproven business model and faces significant challenges as the cell therapy industry is rapidly evolving. Our prospects may be considered speculative and any failure to execute our business strategy could adversely impact our operations and the price of our common stock.
  • We are not profitable as of December 31, 2024, have limited cash flow and, unless we increase revenues and take advantage of any commercial opportunities that arise to expand our POCare business, the perceived value of our company may decrease and our stock price could be affected accordingly.
  • Our research and development programs are based on novel technologies and are inherently risky.
  • Kyslecel may not achieve patient or market acceptance, which could have a material adverse effect on our business.
  • The therapeutic efficacy of Ranpirnase and our other product candidates is unproven in humans, and we may not be able to successfully develop and commercialize Ranpirnase or any of our other product candidates.
  • We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.
  • We require additional capital to support our business, and this capital may not be available on acceptable terms or at all.
  • We conduct certain of our operations in Israel. Conditions in Israel, including the October 7, 2023 attack by Hamas and other terrorist organizations from the Gaza Strip and Israel’s war against them, may affect certain of our operations.
  • Currency exchange fluctuations may impact the results of our operations.
  • We have entered into collaborations and joint ventures and may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
The other 37 risks
  • Our success will depend on strategic collaborations with third parties to develop and commercialize therapeutic product candidates, and we may not have control over a number of key elements relating to the development and commercialization of any such product candidate.
  • Our success depends on our ability to protect our intellectual property and our proprietary technologies.
  • We cannot be certain that the claims in our issued United States methods of use patents will not be found invalid or unenforceable if challenged.
  • Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
  • It may be difficult to enforce a U.S. judgment against us, our officers and directors and the foreign persons named in this Annual Report on Form 10-K in the United States or in foreign countries, or to assert U.S. securities laws claims in foreign countries or serve process on our officers and directors and these experts.
  • We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.
  • We are increasingly dependent on information technology and our systems and infrastructure face certain risks, including cybersecurity and data storage risks.
  • There can be no assurance that we will be able to develop in-house sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product in the United States or overseas, and as a result, we may not be able to generate product revenue.
  • If we are unable to integrate acquired businesses effectively, our operating results may be adversely affected.
  • Risks Related to Our Decentralized Production Units or OMPULs (“DPU & Os”)
  • We may not be able to operate our DPU & Os in all cities or desired locations and the sizes and use of our laboratories in such DPU & Os may be restricted due to zoning, environmental, medical waste, or other licensing regulations.
  • If our existing DPU & O facilities become damaged or inoperable or if we are required to vacate our existing facilities, our ability to perform our tests and pursue our research and development efforts may be jeopardized.
  • Changes in the price and availability of our raw materials could be detrimental to our DPU & O operations.
  • We are dependent on skilled human capital for our DPU & Os.
  • If we are unable to successfully secure our locations and premises, we may be unable to operate out of our DPU & Os or keep our employees and laboratory equipment safe.
  • Our DPU & Os are operated in a heavily regulated industry, and changes in regulations or violations of regulations may, directly or indirectly, reduce our revenue, adversely affect our results of operations and financial condition, and harm our business.
  • Risks Related to Our Trans-Differentiation Technologies for Diabetes and the THM License Agreement
  • THM is entitled to cancel the THM License Agreement.
  • Risks Related to Development and Regulatory Approval of Our Therapies and Product Candidates
  • Research and development of biopharmaceutical products is inherently risky.
  • Extensive industry regulation has had, and will continue to have, a significant impact on our business, especially our product development, manufacturing and distribution capabilities.
  • Regulatory approval may be delayed, limited or denied for a number of reasons, including insufficient clinical data, the product not meeting safety or efficacy requirements or any relevant manufacturing processes or facilities not meeting applicable requirements.
  • We have generated limited revenue from therapeutic product sales, and our ability to generate any significant revenue from product sales and become profitable depends significantly on our success in a number of factors.
  • When we commence any clinical trials, we may not be able to conduct our trials on the timelines we expect.
  • Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences.
  • Our product candidates are biologics, and the manufacture of our product candidates is complex, and we may encounter difficulties in production, particularly with respect to process development or scaling-out of our manufacturing capabilities.
  • Cell-based therapies rely on the availability of reagents, specialized equipment, and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment, and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products.
  • There can be no assurance that we will be able to further develop in-house sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product in the United States or overseas, and as a result, we may not be able to generate product revenue.
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  • We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
  • Risks Related to our Common Stock
  • Our common stock has been delisted from Nasdaq.
  • We have not been able, and may continue to be unable, to timely file periodic reports with the SEC.
  • If we issue additional shares of common stock in the future, it will result in the dilution of our existing stockholders.
  • If the Lender converts its outstanding loan amount into shares representing up to 80% of our outstanding common stock, the Lender could significantly influence the outcome of our corporate matters.
  • Our stock price and trading volume may be volatile, which could result in losses for our stockholders.
  • We do not intend to pay dividends on any investment in the shares of stock of our company.
  • We have identified material weaknesses in our internal control over financial reporting. Failure to achieve and maintain effective internal controls over financial reporting could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner, which could have an adverse impact on our business.

Legal proceedings

See note 23 of Item 8 of this Annual Report on Form 10-K for details of pending legal proceedings.

Except as described therein, we are not involved in any pending material legal proceedings.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
    SEC EDGAROther events
  49. 49
  50. 50
    SEC EDGAROther events
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60